Research lead by Northwestern University in Chicago shows that people with chronic kidney disease and type 2 diabetes are at significantly increased risk of earlier heart disease. The research, which will be presented at the American Heart Association’s Scientific Sessions 2024 later this week by Vaishnavi Krishnan, a researcher at…

A new study led by researchers at the National Institutes of Health (NIH) has discovered that having just one genetic risk variant in the apolipoprotein L1 (APOL1) gene significantly increases the risk of developing kidney disease in people from West Africa. The study, conducted in collaboration with the Human Heredity…

What could be the first precision medicine for APOL1-mediated kidney disease (AKMD) has successfully completed a Phase I trial. People of African ancestry are at greater risk of this disease. The drug, AstraZeneca’s AZD2373, is an antisense oligonucleotide that targets APOL1 mRNA to reduce its protein synthesis and is in…

A combined industry and academia research project aiming to collect biomarkers and find therapeutic solutions for diabetic kidney disease will launch in Montreal with support from Roche, the Quebec Consortium for the Discovery of Medicines (CQDM), the Jewish General Hospital Foundation, local government, and other sources. Brent Richards, a professor…

Novo Nordisk today announced it has notched another win for its GLP-1 agonist semaglutide (Ozempic), this time for reducing cardiovascular disease and slowing kidney disease in diabetic patients. The latest results from the FLOW trial suggest the drug cuts risk of death in this population by as much as 24%.  …

Weight loss by diet and lifestyle can reverse Type 2 diabetes, evidence suggests. Now, new research shows diabetes remission may reduce cardiovascular disease (CVD) risk by 40% and chronic kidney disease (CKD) by 33%. The study appeared in Diabetologia and was led by Edward Gregg, head of the School of…

Results of a clinical trial led by researchers at the University of Washington School of Medicine show an experimental kidney disease drug candidate inhibited the levels of the damaging hormone aldosterone. These findings, published in The Lancet, showed that the drug, BI 690517, produced significant reductions in albumin in the…

New research published in Cell Reports Medicine from a recent clinical trial shows that adhering to a ketogenic diet can effectively control polycystic kidney disease (PKD). The clinical study is the first randomized trial of its kind that examining the ketogenic metabolic therapy as a treatment strategy for PKD. The…

Heart health experts are declaring the overlapping effects of obesity, Type 2 diabetes, chronic kidney disease, and cardiovascular disease as a new syndrome—cardiovascular-kidney-metabolic syndrome, or CKM. This change, they say, is prompting rethinking of how they predict long-term cardiovascular risks. A presidential advisory from the American Heart Association (AHA), published Monday in the…

Researchers used long-read sequencing and identified previously unknown genetic variants that affect the gene associated with the kidney disease Bartter syndrome. The findings are published in the journal Genome Medicine. “Long-read sequencing is increasingly used to uncover structural variants in the human genome, both functionally neutral and deleterious,” wrote the…

A research study led by Massachusetts General Hospital reveals four blood biomarkers that can help predict risk for kidney and heart disease in people with type 2 diabetes and high levels of albumin in their urine. The study, which is published in the journal Circulation, showed that high levels of…

Novartis today announced it will pay $3.2B to acquire Chinook Therapeutics, a Seattle-based biopharmaceutical company with two late-stage medicines in development for rare, severe, chronic kidney diseases, including Immunoglobulin A Nephropathy (IgAN). Such drugs are the vanguard of targeted therapy for IgAN. As Selvaskandan  et al. wrote in one recent…

Research from the Garvan Institute of Medical Research in New South Wales shows that mutations in the TNFAIP3 gene can influence the outcome of kidney disease, with some variants linked to inflammation acting to protect the kidneys. “We wanted to investigate whether inherited differences in how people regulate inflammation could…

A team of researchers at the Perelman School of Medicine at the University of Pennsylvania has identified a new therapeutic target and biomarker indicative of kidney disease. Their research, published in Nature Metabolism, found that metabolic changes to an enzyme “helper molecule” nicotinamide adenine dinucleotide (NAD) helped map changes in…

Sex differences in chronic kidney disease have puzzled researchers for years. Although women are more likely to suffer from chronic kidney disease than men, men are more likely to receive aggressive treatments. For years, researchers have speculated that this is due to women choosing more conservative treatments or men having…